KALARIS THERAPEUTICS, INC. Financing Cash Flow
KALARIS THERAPEUTICS, INC. (KLRS) reported Financing Cash Flow of -$2.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$377.00K.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$1.70M, a 101.58% decline year-over-year.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $47.74M, a 530.06% increase year-over-year.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $155.01M, a 709.86% increase from fiscal 2024.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $19.14M, a 72.85% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $70.50M, a 44.48% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $126.96M, a 54624.57% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.07M 10-Q · filed 2026-08-11 | $45.67M derived: sum of 3 quarters · filed 2026-08-11 | $45.67M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$1.70M 10-Q · filed 2026-05-12 | $46.05M derived: sum of 2 quarters · filed 2026-05-12 | $46.05M derived: sum of 3 quarters · filed 2026-05-12 | $46.05M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $47.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $47.74M derived: sum of 2 quarters · filed 2026-03-17 | $47.74M derived: sum of 3 quarters · filed 2026-08-11 | $155.01M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $107.27M 10-Q · filed 2025-11-12 | $114.84M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $107.27M 10-Q · filed 2026-08-11 | $114.84M derived: sum of 3 quarters · filed 2026-08-11 | $114.84M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $107.27M 10-Q · filed 2026-05-12 | $114.84M derived: sum of 2 quarters · filed 2026-05-12 | $114.84M derived: sum of 3 quarters · filed 2026-05-12 | $119.83M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $7.58M derived: sum of 2 quarters · filed 2026-03-17 | $12.56M derived: sum of 3 quarters · filed 2026-03-17 | $19.14M 10-K · filed 2026-03-17 | $21.00K 10-K · filed 2025-03-07 | ||
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.98M derived: sum of 2 quarters · filed 2025-11-12 | $11.56M 10-Q · filed 2025-11-12 | $21.00K 10-Q · filed 2024-11-12 | $11.57M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $11.56M 10-Q · filed 2025-08-13 | $21.00K 10-Q · filed 2024-08-09 | $11.57M derived: sum of 3 quarters · filed 2025-08-13 | $11.57M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $6.58M 10-Q · filed 2025-05-14 | $6.59M derived: sum of 2 quarters · filed 2025-05-14 | $6.59M derived: sum of 3 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $11.00K derived: sum of 2 quarters · filed 2025-03-07 | $70.50M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $70.48M 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | $70.48M 10-Q · filed 2024-08-09 | ||||||
| 2022-12-31 | $292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $126.72M derived: sum of 2 quarters · filed 2024-03-15 | $126.96M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $126.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $126.67M 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | $244.00K 10-Q · filed 2023-08-03 | ||||||
| 2021-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $232.00K 10-K · filed 2023-02-15 | |||||
| 2021-09-30 | $167.00K 10-Q · filed 2022-11-03 | ||||||
| 2020-12-31 | -$354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $291.98M 10-K · filed 2022-02-10 | |||||
| 2020-09-30 | $292.33M 10-Q · filed 2021-11-05 | ||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $120.92M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $120.92M 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | $120.92M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |